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Introduction. Anticoagulants such as argatroban and heparins (low-molecular-weight and unfractionated) play an immense role in
preventing thromboembolic complications in clinical practice. Nevertheless, they can also have a negative effect on the immune
system. This study is aimed at investigating the influence of these substances on polymorphonuclear neutrophils (PMNs), whose
nonspecific defense mechanisms can promote thrombogenesis. Methods. Blood samples from 30 healthy volunteers were
investigated, whereby PMNs were isolated by density gradient centrifugation and incubated with 0.8 μg/mL of argatroban,
1.0 U/mL of low-molecular-weight heparin (LMWH), 1.0U/mL of unfractionated heparin (UFH), or without drug (control). A
collagen-cell mixture was prepared and filled into 3D μ-slide chemotaxis chambers (IBIDI® GmbH, Germany). Stimulation was
initiated by using a chemokine gradient of n-formyl-methionine-leucyl-phenylalanine (fMLP), and microscopic observation was
conducted for 4.5 hours. The cells’ track length and track straightness, as well as the number of attracted granulocytes, level of
ROS (reactive oxygen species) production, and NET (neutrophil extracellular traps) formation, were analyzed and categorized
into migration distances and time periods. Results. All three anticoagulants led to significantly reduced PMN track lengths, with
UFH having the biggest impact. The number of tracks observed in the UFH group were significantly reduced compared to the
control group. Additionally, the UFH group demonstrated a significantly lower track straightness compared to the control. ROS
production and NET formation were unaffected. Conclusion. Our data provide evidence that anticoagulants have an inhibitory
effect on the extent of PMN migration and chemotactic migration efficiency, thus indicating their potential immune-modulatory
and prothrombotic effects.
1. Introduction
Critically ill patients frequently require anticoagulation in
order to prevent deep vein thrombosis (DVT) and pulmo-
nary embolism (PE). Patients suffering from organ failure
and in need of organ replacement therapy, i.e., receiving
treatment with Extra Corporeal Life Support (ECLS) for
respiratory or cardiocirculatory distress or hemodialysis for
kidney failure, are—even under anticoagulation therapy—at
high risk for thrombotic events due to activation of the coag-
ulation system as mediated by the artificial surfaces involved
[1–3]. Anticoagulation optimization is, therefore, mandatory
in these patients [4, 5]. Clot formation within the membrane
lung or the extracorporeal circuit is the most common
technical complication, with an incidence of up to 22%
[6] during ECLS therapy resulting in high mortality rates
despite technical improvements and more sophisticated
anticoagulation regimens [7].
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In recent years, several studies have provided evidence
for the interaction between polymorphonuclear granulocytes
(PMNs) and the coagulation system. While forming the first
line of innate immunity, imbalanced granulocyte activation
can result in autoimmune diseases and thrombotic complica-
tions [8–10]. Furthermore, leukocyte deposits can be found
in thrombi formed on gas exchange membranes of mem-
brane lungs [11, 12].
Unfractionated heparin (UFH) or low-molecular-weight
heparins (LMWH) are usually used for anticoagulation [7].
The selective factor-IIa (thrombin)-inhibitor argatroban is
an upcoming alternative which is used for anticoagulation
in patients suffering from heparin-induced thrombocytope-
nia [13]. Although studies have repeatedly shown suppres-
sion of granulocyte function in a dose-dependent manner
for UFH and LMWH [14–17], far less is known about the
impact of argatroban on granulocyte migration [18, 19].
The aim of this study was to investigate the impact and
time-dependent viability of UFH, LMWH, and argatroban
on the function of isolated granulocytes by performing
in vitro assays for the comparative analysis of granulocyte
migration capacity, chemotaxis, reactive oxygen species
(ROS) production, and neutrophil extracellular trap forma-
tion (NETosis).
2. Materials and Methods
2.1. Granulocyte Preparation. The experimental setup was
based on our previous studies [20, 21]. Briefly, whole blood
drawn from 30 healthy blood donors (Table 1) with their
informed consent (as approved by the local ethics committee,
Vote No.: 15-101-0043) was anticoagulated using ethylenedi-
aminetetraacetic acid (EDTA) in a final concentration of
1.6mg/mL blood. The blood samples were diluted with 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
and Tyrode solution (modified to 1mM CaCl2 and 1mM
MgCl2). PMNs were isolated by density gradient centrifuga-
tion (756 g) at an ambient temperature of 21°C for 20
minutes with Lympho Spin Medium on top of Leuko Spin
Medium (pluriSelect Life Science, Leipzig, Germany) accord-
ing to the manufacturer’s instructions. After two washing
steps, PMNs were resuspended in RPMI 1640 (Pan-Biotech
GmbH, Aidenbach, Germany) made up with 10% fetal calf
serum (FCS, Sigma-Aldrich GmbH, Steinheim, Germany).
Cells from a single donor were incubated in parallel
at 37°C for 30 minutes with 0.8μg/mL of argatroban
(AGATRA, Mitsubishi Tanabe Pharma GmbH, Düsseldorf,
Germany), 1.0 IU/mL anti-Xa-activity of the LMWH Enoxa-
parin (Clexane, Sanofi-Aventis GmbH, Frankfurt, Germany),
and 1.0 IU/mL anti-Xa-activity of UFH (HEPARIN ROTEX-
MEDICA, ROTEXMEDICA GmbH Arzneimittelwerk, Trit-
tau, Germany) or without drug as a control.
2.2. Microscopy and Live Cell Imaging. To visualize the pro-
duction of ROS 1μMdi-hydro-rhodamine (DHR, Invitrogen
D632, Sigma-Aldrich GmbH, Steinheim, Germany) and,
accordingly, its fluorescence, active oxidized product rhoda-
mine 123 was used. NET formation was detected by staining
released extracellular DNA with 0.5μg/mL of 4′,6-diamidin-
2-phenylindol (DAPI, D9542, Sigma-Aldrich GmbH, Stein-
heim, Germany). Light and fluorescence microscopy was
utilized to examine the cells of all four groups (argatroban,
LMWH, UFH, and control), which were suspended in type
I collagen gel (1.5mg/mL of PureCol with 1.67% FCS,
Advanced BioMatrix Inc., San Diego, CA, USA) and filled
into μ-Slide Chemotaxis chambers (IBIDI GmbH, Martins-
ried, Germany) in accordance with the manufacturer’s pro-
tocol. There is a reservoir on both sides of the chamber’s
gel channels; one was filled with n-formyl-methionine-leu-
cyl-phenylalanine (fMLP 10nM; Sigma-Aldrich GmbH,
Steinheim, Germany) with RPMI/10% FCS and the other
with RPMI with 10% FCS to establish a linear gradient of
the chemoattractant. Each channel was filled with cell-gel
suspensions preincubated with either argatroban, LMWH,
UFH, or none of the aforementioned (control) in order to
exclude interdonor variability.
The PMN observation was carried out with a Leica DMi8
(Leica GmbH, Wetzlar, Germany) with an automatically
adjustable microscope stage and camera (DFC9000, Leica
GmbH, Wetzlar, Germany). To ensure stable test conditions
(37°C, 5% CO2), a stage top incubator (IBIDI) was used. Dur-
ing the observation period of 4.5 hours, fluorescence and
phase contrast images were taken automatically every 30 sec-
onds by the Leica Application Suite X (LAS X 3.0.4.16529,
Leica GmbH, Wetzlar, Germany).
2.3. Image Data Analysis. Image data analysis was based on
previous experiments [20, 21]. Briefly, a total of 540 images
per chamber were analyzed using Imaris software (version
9.0.0, Bitplane, Zurich, Switzerland). To evaluate cell migra-
tion, the software recognized and tracked migrating cells
semiautomatically over a predetermined time period. After
monitoring the migration over the entire observation time,
the 4.5-hour period was divided into blocks of 120 images
per hour and the calculated spots and tracks within these
blocks were analyzed. Data was then exported to Excel
(Microsoft Corp., Redmond, WA, USA), including the total
track length (μm) (length of the migration route of each
individual cell) and the track straightness (fraction of
Euclid track length and total track length showing the cell’s
tendency to migrate directly; higher factors refer to straigh-
ter lines) of each track. A track straightness above 0.2 and
track lengths between 11μm and 200μm were required to
identify and track granulocytes and exclude artefacts. Fur-
thermore, the number of tracked PMNs was analyzed in
categorized migration distances (the blocks of total track
Table 1: Characteristics of the blood donors.
Characteristic Value∗
Number of experiments 30
Sex of subjects 16 females, 14 males
Age (years) 24 (19-58)
Height (cm) 170 (155-193)
Weight (kg) 70 (53-108)
BMI 24.9 (19-29)
∗Data are expressed as the median (range).
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lengths were 11-50, 51-100, 101-150, 151-200, 201-250, and
above 250μm).
Relationships were examined through contingency anal-
yses, and crosstabs were created comparing the observed
and expected normal distribution values.
Pearson’s chi-square test was used to test the signifi-
cance of the differences between the variables. In terms
of the track straightness comparison, a track length above
50μm was required.
To investigate the time point of maximum ROS produc-
tion (Tmax), images were taken every 2.5 minutes during the
4.5-hour observation period and the sum of the surface areas
with DHR/rhodamine 123 staining was calculated. These
surface areas were also recognized semiautomatically by
Imaris and exported to Excel files. A third degree polynomial
trendline was fitted to the parabolic course (time vs. sum of
voxels) to determine the Tmax of ROS (min). Tmax values
above 120min were defined as implausible.
The response of DAPI contact with extracellular DNA
(NET formation) was also analyzed by summing up single
surface areas per time point, which resulted in sigmoidal
curves. The time points at which the half-maximal effects
(Et50) were reached were calculated by population analysis
with Phoenix 64 software (sigmoidal baseline Emax-model;
Certara Inc., Princeton, NJ, USA). ET50 values beyond the
observational period were defined as implausible.
2.4. Flow Cytometry. In addition to the life cell imaging, a
portion of the cells was prepared for flow cytometry (FACS-
Calibur, Becton & Dickinson, Heidelberg, Germany) to ana-
lyze the ROS production with a second method and to
compare the vitality among the four groups using CellQuest
Pro software (version 5.2, Becton-Dickinson Bioscience,
San Jose, USA) and FlowJo (version 10.0.7, FlowJo LLC, Ash-
land, OR, USA). In terms of cell vitality, propidium iodide-
(PI-) negative cells were considered vital.
The materials and methods for quantifying ROS produc-
tion have been described in detail in previous papers [22, 23].
Briefly, cells were preincubated in 500μL of HEPES buffer
and Tyrode solution (modified to 1mM CaCl2 and 1mM
MgCl2), 5μL of DHR (10μM), and 5μL of seminaphtharho-
dafluor (SNARF, 10μM, Invitrogen). Stimulation was
induced by adding either 5μL of fMLP (10μM) and 5μL of
human tumor necrosis factor alpha (TNFα, 1μg/mL, Pepro-
Tech Inc., Rocky Hill, NJ, USA) or 5μL of phorbol-12-myr-
istate-13-acetate (PMA, 10μM, Sigma-Aldrich GmbH).
Finally, 5μL of PI (33671, 1.5mM, Serva Electrophoresis
GmbH, Heidelberg, Germany) was added to detect dead cells.
2.5. Statistical Analysis. All Excel data (Microsoft Excel 2016)
were subsequently transferred to SPSS Statistics (Version 25,
IBM Corp., Armonk, NY, USA), and the Kolmogorov-
Smirnov test was used to confirm normal distribution for
each group.Where there was a normal distribution, the mean
values (MV) were compared, specifying the standard devia-
tion (±SD). Raw data were compared using the Kruskal–
Wallis one-way analysis of variance (ANOVA). Where there
was variance homogeneity (Levene), post hoc analysis was
carried out using the Bonferroni correction or, alternatively,
the Dunnett-T3 test. In nonparametric comparison of
groups, medians were given with the interquartile range
(IQR) and plotted as box plots and lower and upper
quartiles, as well as minima and maxima that had been
calculated. Contingency analyses, crosstabs, and Pearson’s
chi-square test were used to detect significant contexts. p
values below or equal to 0.05 were considered statistically
significant.
3. Results
The control group (n = 2118 tracks) demonstrated a median
track length of 66.3μm (IQR = 85:4 μm) in the first 60
minutes of observation. At 52.6μm (IQR = 79:7 μm), the
median of the argatroban group (n = 2101 tracks) was signif-
icantly lower than that of the control group (p < 0:001). The
LMWH group (n = 1922 tracks) had a median of 66.9μm
(IQR = 74:0 μm), thus not differing from the control, while
the lowest median of 37.0μm (IQR = 67:3 μm) (p < 0:001)
was found in the UFH group (n = 524 tracks) (Figure 1(a)).
Nevertheless, it was possible to observe significant differences
between the argatroban and LMWH groups versus the UFH
group (p < 0:001).
Between minutes 61 and 120, all three verum groups dif-
fered significantly to the control (n = 1198 tracks), which had
a median of 53.6μm (IQR = 72:0 μm) (p < 0:001). For the
argatroban group (n = 989 tracks) and the LMWH group
(n = 897 tracks), the median was 47.3μm (IQR = 68:7 μm)
and 42.6μm (IQR = 55:0 μm), respectively. As before, the
lowest value was found in the UFH group (n = 204 tracks)
with a median of 19.3μm (IQR = 34:7 μm), which also dif-
fered from the LMWH and the argatroban groups
(p < 0:001) (Figure 1(b)).
From minute 121 to 180, there were no differences
between the control (n = 687 tracks), which had a median
of 38.8μm (IQR = 55:2 μm), and the argatroban group
(n = 627 tracks), with a median of 43.8μm (IQR = 59:3 μm),
or the LMWH group (n = 386 tracks) with a median of
35.4μm (IQR = 42:0 μm). Only the UFH group (n = 79 tracks)
differed from the control with a significantly lower median of
27.3μm (IQR = 48:0 μm) (p = 0:039) (Figure 1(c)). The median
of the argatroban group was significantly higher than the
medians of the LMWH and the UFH groups (p = 0:002).
Between minutes 181 and 240, the argatroban group
(n = 412 tracks) was—with a median of 40.8μm
(IQR = 55:8 μm)—the only group that demonstrated a sig-
nificantly higher median than the control. The control
(n = 285 tracks) had a median of 32.0μm (IQR = 46:6 μm)
(p = 0:006) and the LMWH group (n = 146 tracks) had a
median of 28.6μm (IQR = 31:5 μm) (p = 0:001). There
were no differences between the other groups (the UFH
group (n = 35 tracks) showed a median of 26.1μm
(IQR = 24:8 μm)) (Figure 1(d)). No further significant dif-
ferences could be detected in the last 30 minutes of the
observation period (data not shown).
The crosstab containing the observed track counts in
defined length categories, and the expected number of tracks
which were calculated based on an assumed normal distribu-
tion, revealed a significant correlation between drug and
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number of tracks (chi-square ð15Þ = 165, p < 0:001, n =
13552 tracks). The comparison showed no significant devia-
tions in the control and the argatroban groups, for which the
relative deviations were in the range of -1.82 and -4.32%. For
all distance categories above 151μm (-7.77 and -22.1%),
deviations tended to be of higher magnitude in the LMWH
group but did not reach significance. The highest discrep-
ancies between the observed and expected counts were
found in the UFH group. Here, deviations ranged from
-23.0 to -72.9% in the categories beyond 51μm total track
length, indicating that the relative number of nonmigrat-
ing granulocytes (total TL < 50 μm; mean + 35:4%) is ele-
vated and the relative number of active granulocytes
(total TL > 51 μm; mean -44.3%) is reduced (Table 2).
Consequently, only the mean granulocyte counts of the
UFH group (n = 869 tracks) showed a significant deviation
of -31:1 ± 36:9% between the tracked and expected cells per
track length categories, compared to the control group
(n = 4657 tracks) with only 10:6 ± 13:1% deviation
(p = 0:012) (Figure 2).
The comparison of the track straightness showed no dif-
ferences between the control (n = 3139 tracks), which had a
median track straightness of 0.40 (IQR = 0:34), and the arga-
troban group (n = 2778 tracks) with a median of 0.38
(IQR = 0:32). This also applied to the LMWH group
(n = 2307 tracks) with a median of 0.40 (IQR = 0:33). The
straightness of the UFH group (n = 430 tracks), however, dif-
fered significantly from the control (p < 0:001) with a median
of 0.32 (IQR = 0:32).
After excluding one implausibly extreme value, the
fluorescence response of oxidized DHR in life cell imaging
did not differ from the mean Tmax of the control
(66:2 ± 15:5 min, n = 30). Each group demonstrated the fol-
lowing Tmax values: the argatroban group (63:9 ± 12:7 min,
n = 30), the LMWH group (71:8 ± 14:4 min, n = 15), and
the UFH group (68:3 ± 5:45 min, n = 14) (Figure 3).
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Figure 1: Comparison of track length medians of the verum groups with the control group at the observation time periods: 0–60min
(a), 61–120min (b), 121–180min (c), and 181–240min (d). Cont: control; Arga: argatroban; LMWH: low-molecular-weight heparin;
UFH: unfractionated heparin.
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After excluding five implausible measurements with
ET50values above 400min, more than eleven ET50 values could
be evaluated for each group. The mean ET50 values were as fol-
lows: the control (159 ± 37:8 min, n = 23), the argatroban
group (175 ± 53:2 min, n = 22), the LMWH group
(163 ± 25:5 min, n = 13), and the UFH group
(185 ± 36:6 min, n = 11) (Figure 4).
In the FACS analysis of the fMLP-stimulated granulo-
cytes, the control (n = 22) showed a median rhodamine 123
(ROS production) fluorescence intensity of 115 (IQR = 437),
the argatroban group (n = 22) a median of 89 (IQR = 193:5),
the LMWH group (n = 10) a median of 175 (IQR = 139),
and the UFH group (n = 12) a median of 66 (IQR = 362). In
the positive control (PMA-stimulated), a median of 4254
(IQR = 3456) was obtained in the control group (n = 22),
and medians of 3390 (IQR = 3847), 3889 (IQR = 3125), and
4555 (IQR = 4472) were obtained in the argatroban group
(n = 22), the LMWH group (n = 10), and the UFH group
(n = 12), respectively. Thus, all medians of fluorescence inten-
sity caused by ROS production were found to be indistinguish-
able (Figure 4).
After the 30-minute preincubation period with the drugs,
cells of the argatroban group (n = 23) showed a median of
98.6% (IQR = 1:50%) vital granulocytes. In the LMWH
group (n = 11) with a median of 98.7% (IQR = 2:15%), vital
cells could be found, which was similar to that of the UFH
group (n = 12) with a median of 98.8% (IQR = 2:30%).
Therefore, compared to the control (n = 23) with a median
Table 2: Comparison of numbers between tracked and expected granulocytes per track length category: number of tracks of the UFH group
shows the greatest deviations compared to the control group.
Number of tracked granulocytes in categorized migration distances (track length)
Total track length (μm) 11-50 51-100 101-150 151-200 201-250 >250 Total Mean
Observation groups
Control
Number of tracks 2042 1220 722 371 174 128 4657 776.2
Expected number 2208.2 1218.5 663.2 317.9 150.2 99.0 4657 776.2
Difference (%) -7.53 0.12 8.86 16.7 15.9 29.3 63.4 10.6
Argatroban
Number of tracks 2184 1131 608 299 144 96 4462 743.7
Expected number 2115.8 1167.5 635.5 304.6 143.9 94.8 4462.1 743.7
Difference (%) 3.23 -3.13 -4.32 -1.82 0.08 1.24 -4.72 -0.79
Enoxaparin
Number of tracks 1642 1020 519 218 106 59 3564 594
Expected number 1690.0 932.6 507.6 243.3 114.9 75.7 3564.1 594
Difference (%) -2.84 9.38 2.25 -10.4 -7.77 -22.1 -31.5 -5.25
UFH
Number of tracks 558 175 81 37 13 5 869 144.8
Expected number 412.1 227.4 123.8 59.3 28.0 18.5 869.1 144.8
Difference (%) 35.4 -23.0 -34.5 -37.6 -53.6 -72.9 -186.2 -31.0
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Figure 2: Number of tracked granulocytes: there were no significant differences in the relative deviations between the argatroban, LMWH,
and control groups. Only the UFH group differed significantly from the control (p = 0:012). LMWH: low-molecular-weight heparin; UFH:
unfractionated heparin.
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of 98.8% (IQR = 2:00), no significant differences could be
observed.
4. Discussion
This study investigated the impact of the clinically used anti-
coagulants UFH, the LMWH Enoxaparin, and the direct
thrombin-inhibitor argatroban on isolated granulocytes in
terms of granulocyte migration, time dependency of ROS
production and NET formation, and vitality.
PMNs were obtained from healthy volunteers of both
sexes without prior mobilization and were then incubated
in parallel with UFH, LMWH, and argatroban after two
washing steps in order to exclude any external influences
on baseline granulocyte function, e.g., infections or humoral
and hormonal factors. Therefore, measurements of humoral
factors such as clotting factors, chemokines, or cytokines
were not performed. All three anticoagulants are known to
reduce inflammatory mediators produced by blood cells
and other tissues (e.g., IL-6, IL-8, TNFα, or nuclear factor
kappa B (NFκ-B)) after longer incubation times, ranging
from three hours to four weeks [18, 24, 25].
UFH is used in clinical routine since 1971. It activates
antithrombin and exerts its anticoagulatory effects by facili-
tating the interaction between antithrombin (AT) and
thrombin, as well as the interaction with coagulation factor
X [26]. LMWH directly inhibits coagulation factor X, creat-
ing a dose-dependent anticoagulant effect. It has also been
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Figure 3: Neither the response of oxidized DHR nor the time course of DAPI-free DNA complex formation showed statistically significant
mean differences between the four groups. NET-forming (ET50, blue) and ROS production (Tmax, red). LMWH: low-molecular-weight
heparin; UFH: unfractionated heparin.
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Figure 4: FACS analysis of ROS production: comparisons between fMLP (blue) and PMA- (red-) stimulated explorations of the four groups
showed no differences. LMWH: low-molecular-weight heparin; UFH: unfractionated heparin.
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used in clinical routine for two decades, and its use has
been proven safe in medical and surgical patients [27, 28].
Argatroban is a direct thrombin inhibitor used to manage
anticoagulation during HIT II [13]; its feasibility for antic-
oagulation during ECLS and hemodialysis has already been
proven [29, 30].
The dosages of the three anticoagulants under investiga-
tion were chosen to match clinical routine. According to
the manufacturer, an activated prothrombin time (aPTT,
baseline 27-36 seconds) prolonged by a factor of 1.5 to 3 is
required for therapeutic anticoagulation with argatroban
[31]. Plasma levels of 0.8μg/mL of argatroban result in an
aPTT of 62-65 seconds [32]. The dosage for the LMWH
Enoxaparin was chosen according to the manufacturer’s pre-
scription information for therapeutic anticoagulation. After a
subcutaneous application of 1mg/kg bodyweight twice daily,
plasma levels of anti-Xa-activity of 1.1 IU/mL can be mea-
sured in the steady state [33]. An aPTT prolonged by a factor
of 1.5 to 2.5 is required for therapeutic anticoagulation with
UFH [34]. The concentration of UFH was chosen based on
the same parameters as for Enoxaparin, with—due to ethical
considerations—an added 1 IU/mL of anti-Xa-activity to
avoid having to administer an UFH infusion to healthy vol-
unteers for several hours in order to achieve stable aPTT
values. Furthermore, adjustment of UFH dosage based on
anti-Xa assays has been proven more reliable than aPTT-
based assays in terms of achieving a faster rate of therapeutic
anticoagulation with less variance [35].
For the migration assay, neutrophil activation was initi-
ated by using the chemoattractant fMLP. Stimulation with
fMLP has been proven in several studies to be a practicable
way to induce NET formation [36]. It enabled the observa-
tion of the cellular events in our live cell imaging setting,
which was a prerequisite for the precise evaluation of migra-
tion. We decided against activation with PMA for the live cell
imaging because of the agent’s already known substantial
impact on granulocyte function [37]. In our flow cytometric
assay, granulocyte activation for ROS production was
achieved using fMLP, with the addition of PMA to serve as
a positive control [38]. Unpublished data from our labora-
tory reveal an approximate 50% ET50 reduction with a
PMA concentration above 10nM.
Migration assays were performed using a collagen I
matrix to mimic the physiological extracellular environment.
Our collagen I-based experimental set-up enabled live cell
imaging and parallel testing of migration, ROS production,
and NETosis [20, 21]. In addition, a well-established method
of FACS analysis was used for respiratory burst measure-
ment [22, 23].
All three anticoagulants under investigation significantly
reduced neutrophil migration compared to the control
group. While argatroban already began to suppress PMN
migration within the first observation period, LMWH took
longer to exert its effect. The biggest impact was measured
in the UFH group during the first 180 minutes of the
experiment. Furthermore, UFH preincubated granulocytes
showed significantly lower relative track numbers of migrat-
ing cells compared to the control. Additionally, track
straightness was reduced significantly, resulting in less effi-
cient migration in the UFH group. Heparin and LMWH
are known to reduce granulocyte migration in various clini-
cal settings. In other studies, researchers found reduced gran-
ulocyte infiltration after traumatic brain injury when using
the same dosing regimen for UFH and LMWH [39, 40].
Our observations match the findings of these studies, despite
our study having used a different matrix. These inhibitory
effects have been attributed to stimuli unrelated to the antico-
agulant capacities of UFH and LMWH, such as inhibition of
thrombin, Mac-1, interaction with heparin-binding proteins,
NFκ-B, growth factors, and cytokines [39, 40]. After the
administration of argatroban, a lower infiltration of granulo-
cytes into the brain tissue of rats suffering traumatic brain
injury was observed; another study showed reduced granulo-
cyte infiltration into the liver tissue of rats suffering from
fatty liver disease [18, 19]. Both studies postulate that this
effect is due to thrombin inhibition, which leads to increased
plasma levels in both the brain and liver tissue and serves as a
potent activator of granulocytes. After the administration of
argatroban in rats with sepsis, Fuchs et al. observed improved
intestinal microcirculation with reduced leucocyte adhesion
and improved capillary perfusion [41]. These effects were
also attributed to thrombin inhibition and subsequent
reduction of microthrombi, as well as reduced endothelial
activation with less leukocyte adherence. Thrombin also
has direct proinflammatory effects due to its receptor (prote-
ase-activated receptor (PAR)), resulting in increased levels of
AKT, NFκ-B, and caspase-3 [42]. In a recent study by Bulani
et al., a significant improvement in diabetic cardiomyopathy
could be detected [43]. The administration of argatroban
reduced granulocyte migration in the first 120 minutes of
both experiments. Surprisingly, in the present work, neutro-
phils incubated with argatroban showed greater migration
distances after 120 minutes compared to the control, though
migration during this time period was significantly reduced
compared to baseline values for both groups.
In our study, no significant differences in ROS produc-
tion between the groups investigated could be observed,
whether it concerned fluorescence intensity or its chrono-
logical sequence. This result is in line with the findings of
a study by Xu et al.; the researchers could not observe
reduced ROS production following a daily subcutaneous
administration of 1.5mg of Enoxaparin in a rat model of
liver fibrosis and splenectomy [44]. Xu et al. speculated that
Enoxaparin had an inhibitory effect on thrombin and plate-
lets. In contrast, Li and coworkers showed reduced ROS
production in cell cultures of the bronchial epithelial cell
line HBE 16 after incubation with 50 to 450 IU/mL of
UFH [45]. Li et al.’s study postulated that the inhibitory
effects of UFH on intracellular signaling pathways are unre-
lated to the anticoagulant effects responsible for this obser-
vation. Hence, the dosages used to achieve reduced ROS
production are far beyond the plasma levels of UFH used
in our study and far beyond clinical routine.
Concerning the applied dosages of the three substances
investigated in our experiment, no significant NET forma-
tion differences between the groups could be found. Contrary
findings regarding the absolute amounts, but not the chrono-
logical sequence, were made by other research groups in
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studies on UFH and LMWH. Fuchs et al. observed signif-
icantly reduced levels of NETs after administration of
high-dose UFH at 100μg/mL, which is equivalent to
approximately 10 IU/mL [15]. Reduced NET formation
was observed by Manfredi et al. for an identical dose of
1 IU/mL of Enoxaparin [17]. This contrary effect observed
in the latter study may be due to different handling regimens
concerning how the PMNs were obtained and isolated. In
Manfredi et al.’s study, granulocytes were incubated for 30
minutes at 4°C with Enoxaparin, which may have had an
inhibitory effect due to hypothermia. To the best of our
knowledge, no literature on the interaction of argatroban
and NET formation is currently available.
Finally, in our experimental setting, none of the three
substances under investigation affected the study’s viability.
Although UFH is known to be able to induce apoptosis in
granulocytes in a dose-dependent manner via the CD61b
pathway, plasma levels above 20–50 IU/mL are required to
have a significant effect [14, 16, 45]. As previously men-
tioned, this dosage is far beyond a rational anticoagulation
regime.
Further studies are needed to elucidate the different or
additional effects due to PMNs coming into contact with arti-
ficial surfaces or the shear force effects induced by extracor-
poreal systems.
5. Conclusion
In conclusion, our in vitro study with a collagen-I-matrix
provides evidence that the PMN activity sequence is initial-
ized with migration before the cells start to change their
shape and produce ROS followed by NET formation. Our
data show that anticoagulants in therapeutic dosage, espe-
cially UFH, have an inhibitory effect on the ability of granu-
locytes to migrate, as well as the extent of migration and the
ability to migrate efficiently. Anticoagulants might, therefore,
have immune modulatory effects. It could be hypothesized
that PMNs are less able to migrate in anticoagulated patients.
Furthermore, it could be speculated that PMNs of anticoagu-
lated patients could stick to artificial surfaces due to their
reduced migration capacity, resulting in a prothrombotic
state that might affect therapy with extracorporeal devices.
Other granulocyte functions were not affected, and the avail-
able literature suggests that higher doses of anticoagulants
are required for the inhibition of these functions.
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